SK Chemicals Reports Q2 Profit Amid Pharma Division Struggles

SK Chemicals successfully returned to profitability in the second quarter, reporting an operating profit of $6.6 million on a consolidated basis. However, its pharmaceutical division continues to face challenges. The company, which abandoned plans to sell its pharmaceutical business earlier this year, highlighted that retaining the division aligns better with its strategic objectives, raising curiosity about its next steps.

According to industry reports dated August 12th, SK Chemicals recorded consolidated sales of $309 million, marking an 11.5% year-on-year growth. Operating profit reached $6.6 million, reflecting a shift to profitability, with net profit standing at $3.8 million. On a standalone basis, sales increased 11.6% to $257 million, while operating profit surged 58.9% to $23.4 million.

This positive performance was mainly driven by the Copolyester segment, while the pharmaceutical division lagged behind. Pharmaceutical sales declined from $64 million in Q2 2023 to $60.1 million in the same period this year, with a sequential drop from $64.5 million in Q1 2024. Operating profit in this segment also decreased from $3.7 million in Q2 2023 to $3.1 million in Q1 2024, further dipping to $2.8 million in Q2 2024.

In contrast, SK Bioscience, a subsidiary, saw its operating losses reduce from $26.3 million in Q2 last year to $14.8 million this quarter. The bio division is expected to perform well in Q3, fueled by upcoming shipments of flu and Novavax COVID-19 vaccines.

During an IR presentation, the company attributed the pharmaceutical division’s performance decline to lower sales and price cuts, which have pressured margins. SK Chemicals plans to enhance profitability in Q3 through sales recovery of existing products and the launch of new offerings, although specific product details remain undisclosed.

The company also unveiled its mid- to long-term strategic goals, focusing on increasing the value of herbal medicines, expanding its global CDMO business, and driving R&D initiatives. However, there are concerns over potential overlaps in the CDMO space, given SK Bioscience and SK Pharmteco’s existing operations. SK Pharmteco specializes in cell and gene therapies (CGT), while SK Bioscience is focused on vaccines. Yet, CGT overlaps could arise following SK Bioscience’s acquisition of IDT Biologika.

An SK Chemicals spokesperson addressed these concerns, stating, “While we cannot comment on other companies’ business directions, our CDMO operations focus on complex formulation clinical trials, regulatory approvals, and commercialization, initiated last year.”

Despite the growth in its bio segment, the ongoing struggles in the pharmaceutical division have led to speculation about a possible future sale. The company previously canceled the sale after four unsuccessful attempts but has firmly stated that there are no plans to reconsider it at present. Industry observers are closely watching how SK Chemicals will stabilize its operations in the months ahead.